Natalja Van Biesen

Ms. Natalja Van Biesen

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2025 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
NBNatalja Van Biesen
Natalja Van Biesen
PCPiet Cools
Piet Cools
EMEline Meyers
Eline Meyers
Background/Objectives: DNA extraction from dried blood spot (DBS) samples is often applied in neonatal screening programs. Although various methods to extract DNA from DBSs have been described, the optimal approach remains unclear. Therefore, this study aimed to compare and optimize extraction methods to establish a reliable and efficient protocol for human DNA extraction from DBSs. Methods: We conducted a back-to-back comparison of five different DNA extraction methods on 20 DBS samples: three column-based kits (QIAamp DNA mini kit, High Pure PCR Template Preparation kit, DNeasy Blood & Tissue kit) and two in-house boiling methods (one using TE buffer, one using Chelex-100 resin). DNA recovery was measured with DeNovix DS-11 and ACTB qPCR. Further optimization of elution volumes and starting material was performed on the best-performing methods (sample size = 5). Additionally, T-cell receptor excision circle (TREC) DNA was assessed by qPCR as an application. Results: The Chelex boiling method yielded significantly (p < 0.0001) higher ACTB DNA concentrations compared to the other methods. Column-based methods showed low DNA recovery, except for Roche, which showed significantly (p < 0.0001) higher DNA concentrations than the other column-based methods, as measured by DeNovix DS-11. Decreasing elution volumes (150 vs. 100 vs. 50 µL) increased ACTB DNA concentrations significantly, while increasing starting material (two vs. one 6 mm spot) did not. Conclusions: We identified an easy and cost-effective optimized DNA extraction method using Chelex from DBSs, with an elution volume of 50 µL and 1 × 6 mm DBS punch, which is particularly advantageous for research in low-resource settings and large populations, such as neonatal screening programs.

19 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
EMEline Meyers
Eline Meyers
NBNatalja Van Biesen
Natalja Van Biesen
LRLiselore De Rop
Liselore De Rop
TBTine De Burghgraeve
Tine De Burghgraeve
Marina DigregorioMarina Digregorio
Marina Digregorio
PCPiet Cools
Piet Cools
Background: T-cell receptor excision circles (TRECs) and kappa-deleting recombination excision circles (KRECs) are markers of recent thymic and bone marrow output, respectively. As they have previously been associated with immunosenescence, we aimed to investigate their association with anti-spike SARS-CoV-2 (S1RBD) IgG antibody response after COVID-19 vaccination in nursing home residents (NHRs) and staff (NHS). Methods: We measured TREC and KREC levels and S1RBD IgG antibody levels from dried blood spots (DBSs) using in-house qPCRs and a commercial ELISA kit, respectively, in 200 participants (50 NHRs and 150 NHS). DBSs were collected in April 2021, approximately two months after primary course COVID-19 vaccination (BNT162b2). We assessed the association between TREC and KREC as dependent variables and age, sex, infection-priming status, and post-vaccination S1RBD-specific IgG concentrations as independent variables by simple and multiple linear regression. Results: TREC and KREC levels were significantly lower in NHRs compared with NHS and were negatively correlated with age (p < 0.001). Neither TREC nor KREC levels were significantly associated with SARS-CoV-2 antibody concentrations (p > 0.05). Conclusions: In our study population, TREC and KREC levels decreased with age and were statistically significantly lower in NHRs than NHS. They were, however, not associated with the antibody response after COVID-19 vaccination. Yet, additional research is warranted to explore their potential relevance in cellular immune responses or in combination with other biomarkers of immune function.

24 June 2026 in Archives of Public Health
Verified
Journal Article
Open access
LRLiselore De Rop
Liselore De Rop
EMEline Meyers
Eline Meyers
NBNatalja Van Biesen
Natalja Van Biesen
TBTine De Burghgraeve
Tine De Burghgraeve
Marina DigregorioMarina Digregorio
Marina Digregorio
Jan VerbakelJan Verbakel
Jan Verbakel
Background: To characterize real-world COVID-19 vaccine-induced protection, we assessed breakthrough infections and protective antibody thresholds among fully vaccinated nursing home residents (NHR) and staff (NHS). Methods: We conducted a cohort study to assess infection rates and risk factors of symptomatic breakthrough infections in 1605 NHR and 1200 NHS (2021) and 483 NHR (2022) in Belgium using multivariable Cox proportional hazards models adjusted for potential confounders. Additionally, a case-control analysis was used to compare pre-infection and peak vaccine response antibody levels between breakthrough cases and matched controls. Receiver Operating Characteristic (ROC) and net benefit models were fitted to evaluate the protective antibody thresholds in clinical decision making. Results: In 2021, breakthrough infection incidence was 10.7 (95%CI 8.6–13.2) per 100 person-years in NHS and 2.4 (95%CI 1.59–3.46) in NHR. This rose to 10.6 (95%CI 8.3–13.3) in NHR in 2022. Prior infection was protective in NHS (hazard ratio (HR) 0.25, 95%CI 0.13–0.46) and NHR (HR 0.2, 95%CI 0.05–0.87). In NHS, younger age (HR 1.02, 95%CI 1.01–1.04) and Delta circulation (HR 9.52, 95%CI 2.65–34.21) and in NHR, Omicron BA.5 circulation (HR 17.95, 95%CI 2.35-137.13) increased infection risk. Breakthrough cases had lower pre-infection and peak vaccine antibody levels than controls. Protective antibody thresholds were identified and were higher for infections during Omicron than Delta. Using these antibody thresholds to guide vaccination adds value at low risk thresholds, though net benefits were modest. Conclusion: Breakthrough infections affected a minority of vaccinated NHR and NHS. Risk depended on age, prior infection, and circulating variants. Lower antibody levels in cases support their protective role, though thresholds are variant-specific. Our findings support tailored vaccine strategies in this vulnerable population.